Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ondansetron + metoclopramide
- Development stage
- Phase 4
- Lead developer
- GlaxoSmithKline and Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intramuscular
01
Overview
Ondansetron + metoclopramide is a combination of two antiemetic medications used to prevent and treat nausea and vomiting. Ondansetron is a selective 5-HT3 receptor antagonist, while metoclopramide is a dopamine antagonist and prokinetic agent. This combination has been studied for post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Studies suggest that the combination may be more effective than either agent alone in certain clinical scenarios, particularly after sleeve gastrectomy.
- Other names
- metoclopramide and ondansetron combination
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on ondansetron + metoclopramide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ondansetron + metoclopramide.